Perindopril

Angiotensin Converting Enzyme Inhibitor — CARDIOVASCULAR SYSTEM

Key facts

Perindopril is an ofp drug in the Angiotensin Converting Enzyme Inhibitor class catalogued in DrugCentral. It was first approved by the FDA in 1993. Its mechanism of action is classified as Angiotensin-converting Enzyme Inhibitors. DrugCentral lists 1 molecular target, including ACE. Recorded indications include Hypertensive disorder and Myocardial Infarction Prevention.

• Approval status: ofp (first approved 1993 by the FDA).
• Drug class: Angiotensin Converting Enzyme Inhibitor.
• Mechanism of action: Angiotensin-converting Enzyme Inhibitors.
• Molecular targets: ACE (1 listed in DrugCentral).
• Indications: Hypertensive disorder and Myocardial Infarction Prevention.
• ATC code: C09AA04 (ACE inhibitors, plain).
• Molecular formula: C19H32N2O5; molecular weight 368.47 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (2)

• Hypertensive disorder
• Myocardial Infarction Prevention

Off-label uses (5)

• Atrial fibrillation
• Chronic heart failure
• Diabetic renal disease
• Diastolic heart failure
• Nondiabetic Proteinuric Nephropathy

Contraindications (12)

• Acute cerebrovascular insufficiency
• Angioedema
• Bone marrow depression
• Disease of liver
• Disorder of connective tissue
• Hereditary angioneurotic edema
• Hyperkalemia
• Kidney disease
• Low blood pressure
• Neutropenic disorder
• Pregnancy, function
• Renal artery stenosis

Mechanism & targets

• Mechanism of action (MoA): Angiotensin-converting Enzyme Inhibitors
• Established pharmacologic class: Angiotensin Converting Enzyme Inhibitor

Molecular targets (1)

Target	Gene	Action	Activity
Angiotensin-converting enzyme	ACE	inhibitor	IC50 8.82

Regulatory approvals (1)

Date	Agency	Marketed as	Applicant	Orphan
1993-12-30	FDA	—	SYMPLMED PHARMS LLC

ATC classification

ATC code	Therapeutic hierarchy
C09AA04	CARDIOVASCULAR SYSTEM › AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM › ACE INHIBITORS, PLAIN › ACE inhibitors, plain
C09BA04	CARDIOVASCULAR SYSTEM › AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM › ACE INHIBITORS, COMBINATIONS › ACE inhibitors and diuretics
C09BB04	CARDIOVASCULAR SYSTEM › AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM › ACE INHIBITORS, COMBINATIONS › ACE inhibitors and calcium channel blockers
C09BX01	CARDIOVASCULAR SYSTEM › AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM › ACE INHIBITORS, COMBINATIONS › ACE inhibitors, other combinations
C09BX02	CARDIOVASCULAR SYSTEM › AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM › ACE INHIBITORS, COMBINATIONS › ACE inhibitors, other combinations
C09BX04	CARDIOVASCULAR SYSTEM › AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM › ACE INHIBITORS, COMBINATIONS › ACE inhibitors, other combinations
C09BX06	CARDIOVASCULAR SYSTEM › AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM › ACE INHIBITORS, COMBINATIONS › ACE inhibitors, other combinations
C10BX11	CARDIOVASCULAR SYSTEM › LIPID MODIFYING AGENTS › LIPID MODIFYING AGENTS, COMBINATIONS › Lipid modifying agents in combination with other drugs
C10BX12	CARDIOVASCULAR SYSTEM › LIPID MODIFYING AGENTS › LIPID MODIFYING AGENTS, COMBINATIONS › Lipid modifying agents in combination with other drugs
C10BX13	CARDIOVASCULAR SYSTEM › LIPID MODIFYING AGENTS › LIPID MODIFYING AGENTS, COMBINATIONS › Lipid modifying agents in combination with other drugs

Pharmacogenomics

Drug-label and guideline annotations from PharmGKB and CPIC.

• Swissmedic label: G6PD · Actionable PGx

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Acute kidney injury	959.6
Lactic acidosis	494.9
Hyponatraemia	445.9
Hyperkalaemia	417.9
Systemic lupus erythematosus	348.8
Sensitisation	338.6
Glossodynia	316.9
Polycystic ovaries	315.1
Blood pressure systolic increased	307.0
Drug interaction	304.9
Pemphigus	292.6
Blood pressure increased	285.5

Chemical structure

• Molecular formula: C₁₉H₃₂N₂O₅
• Molecular weight: 368.47 g/mol
• CAS number: 82834-16-0
• InChIKey: IPVQLZZIHOAWMC-QXKUPLGCSA-N
• PubChem CID: 107807

CCC[C@H](N[C@@H](C)C(=O)N1[C@H]2CCCC[C@H]2C[C@H]1C(O)=O)C(=O)OCC

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Perindopril used for?

DrugCentral lists the following indications for Perindopril: Hypertensive disorder and Myocardial Infarction Prevention.

How does Perindopril work?

Perindopril is classified as Angiotensin-converting Enzyme Inhibitors; its molecular targets in DrugCentral include ACE (inhibitor).

When was Perindopril first approved?

Perindopril was first approved by the FDA in 1993.

What drug class does Perindopril belong to?

Perindopril is in the Angiotensin Converting Enzyme Inhibitor class.

What is the chemical formula of Perindopril?

Perindopril has the molecular formula C19H32N2O5 and a molecular weight of 368.47 g/mol.

Sources

• DrugCentral drug card 2108 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL1200343 — compound record and bioactivity
• PubChem CID 107807 — chemical identifiers
• DrugBank DB00790 — drug record
• FDA UNII 2UV6ZNQ92K — substance identity
• DailyMed: FDA labels for Perindopril — current prescribing information (label search)
• UniProt P12821 (ACE) — target protein
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral
• PharmGKB / CPIC — pharmacogenomic label annotations

How this page is built: methodology · editorial policy & corrections.